Health and Fitness Health and Fitness
Fri, August 3, 2012
[ Fri, Aug 03rd 2012 ] - Market Wire
Marina Biotech Announces Worldwide Non-Exclusive Licensing Agreement for Nucleic Acid Chemistry
[ Fri, Aug 03rd 2012 ] - Market Wire
Concord Medical to Report Second Quarter 2012 Financial Results on August 20, 2012
Thu, August 2, 2012
[ Thu, Aug 02nd 2012 ] - Market Wire
Galapagos delivers solid half year results 2012
[ Thu, Aug 02nd 2012 ] - Market Wire
Rosetta Genomics Announces Pricing of Public Offering of 5.5 Million Ordinary Shares
[ Thu, Aug 02nd 2012 ] - Market Wire
Accuray anuncia el primer Sistema CyberKnife en Sudamrica
[ Thu, Aug 02nd 2012 ] - Market Wire
MethylGene Reports Second Quarter 2012 Financial .. s and Provides an Update on its Clinical Programs
[ Thu, Aug 02nd 2012 ] - Market Wire
MiMedx Group to Present at the Canaccord Genuity Annual Growth Conference
[ Thu, Aug 02nd 2012 ] - Market Wire
Medivation Announces Second Quarter 2012 Financial Results Teleconference on August 9, 2012
[ Thu, Aug 02nd 2012 ] - Market Wire
Watson Applauds GPhA Study Demonstrating $1 Trill .. Prescription Drug Savings from Generic Medicines
[ Thu, Aug 02nd 2012 ] - Market Wire
Nektar to Announce Financial Results for the Seco .. y, August 9, 2012, After Close of U.S.-Based Fina
[ Thu, Aug 02nd 2012 ] - Market Wire
MSA Declares Third Quarter Dividend
[ Thu, Aug 02nd 2012 ] - Market Wire
Mylan Applauds Study Highlighting $1 Trillion in .. Care System Due to Generic Drugs Over Past Decade
[ Thu, Aug 02nd 2012 ] - Market Wire
USANA Recognized For The Fourth Consecutive Year .. erica's 'Best Places to Work' By Outside Magazine
[ Thu, Aug 02nd 2012 ] - Market Wire
Acura Pharmaceuticals Supports the Stop Tampering of Prescription Pills Act of 2012
[ Thu, Aug 02nd 2012 ] - Market Wire
Mylan Signs Agreement with Gilead to Accelerate A .. ixed-Dose Combination ARVs Containing Emtricitabi
[ Thu, Aug 02nd 2012 ] - Market Wire
Waters and Nonlinear Dynamics to Co-Develop Next .. arch Solutions for Large-Scale, Complex Data Sets
[ Thu, Aug 02nd 2012 ] - Market Wire
Alliqua Names Stephen A. Brigido, D.P.M. Chairman of Scientific Advisory Board
[ Thu, Aug 02nd 2012 ] - Market Wire
Solta Medical, Inc. Prices $15 Million Public Offering of Common Stock
[ Thu, Aug 02nd 2012 ] - Market Wire
Accuray Announces First CyberKnife System in South America
[ Thu, Aug 02nd 2012 ] - Market Wire
ZYTO Corp Announces Expansion of Scientific Advisory Board
[ Thu, Aug 02nd 2012 ] - Market Wire
Paladin Reports Second Quarter 2012 Results-Increases 2012 Revenue Guidance to Over $200 Million
[ Thu, Aug 02nd 2012 ] - Market Wire
Bioheart Receives $ 2 Million Term Sheet Investme .. bal Leader in Healthcare in Latin America and Eur
[ Thu, Aug 02nd 2012 ] - Market Wire
Implant Sciences Awarded Follow-On Order to China for Aviation Security
[ Thu, Aug 02nd 2012 ] - Market Wire
Comprehensive Care Corporation Names Colonel Ramo .. Advisor To Maximize its Market Share with New Pha
Wed, August 1, 2012
[ Wed, Aug 01st 2012 ] - Market Wire
Haemonetics Completes Acquisition of Pall's Transfusion Medicine Business
[ Wed, Aug 01st 2012 ] - Market Wire
Solta Medical, Inc. Announces Proposed Public Offering of Common Stock
[ Wed, Aug 01st 2012 ] - Market Wire
NuVasive to Participate in the Canaccord Genuity Growth Conference
[ Wed, Aug 01st 2012 ] - Market Wire
Alexza Announces Management Promotions
[ Wed, Aug 01st 2012 ] - Market Wire
Halozyme Confirms Baxter Has Received A Complete Response Letter For HyQ BLA
[ Wed, Aug 01st 2012 ] - Market Wire
Sarepta Therapeutics to Present Company Overview .. e 32nd Canaccord Genuity Annual Growth Conference

Sarepta Therapeutics to Present Company Overview at the 32nd Canaccord Genuity Annual Growth Conference


Published on 2012-08-01 13:21:37 - Market Wire
  Print publication without navigation


August 01, 2012 16:05 ET

Sarepta Therapeutics to Present Company Overview at the 32nd Canaccord Genuity Annual Growth Conference

Webcast Accessible via Sarepta Therapeutics Website

CAMBRIDGE, MA--(Marketwire - Aug 1, 2012) - Sarepta Therapeutics (NASDAQ: [ SRPT ]), a developer of innovative RNA-based therapeutics, announced today that it is scheduled to present at the 32nd Canaccord Genuity Annual Growth Conference in Boston, MA on Wednesday, August 15, 2012 at 4:30 p.m. Eastern Time. Chris Garabedian, Sarepta's President and CEO, will be the presenter.

The presentation will be webcast live under the events section of Sarepta Therapeutics' website at [ www.sareptatherapeutics.com ] and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Sarepta Therapeutics

Sarepta Therapeutics -- formerly AVI BioPharma -- is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at [ www.sareptatherapeutics.com ].


Contributing Sources